Olanzapine/fluoxetine combination for bipolar depression and other mood disorders: A review

Drugs of Today

Volumn 42, Issue 3, 2006, Pages 185-192

  Owen, Richard T ^a  

^a Medical Information Department   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; CITALOPRAM; CLOZAPINE; DOPAMINE; ESCITALOPRAM; FLUOXETINE; LAMOTRIGINE; LITHIUM; NEUROLEPTIC AGENT; NORADRENALIN; NORTRIPTYLINE; OLANZAPINE; PAROXETINE; PLACEBO; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID; VENLAFAXINE; ZIPRASIDONE;

ABNORMAL THINKING; ASTHENIA; BIPOLAR DEPRESSION; CLINICAL TRIAL; DIARRHEA; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFECT; DRUG ELIMINATION; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; EXTRAPYRAMIDAL SYMPTOM; HUMAN; INCREASED APPETITE; MAJOR DEPRESSION; MANIA; META ANALYSIS; MOOD DISORDER; NAUSEA; NONHUMAN; PERIPHERAL EDEMA; PHARYNGITIS; QUALITY OF LIFE; REVIEW; RISK FACTOR; SIDE EFFECT; SOMNOLENCE; SYSTEMATIC REVIEW; THORAX PAIN; TREMOR; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

ANIMALS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CLINICAL TRIALS; DRUG THERAPY, COMBINATION; FLUOXETINE; HUMANS; MOOD DISORDERS; SEROTONIN UPTAKE INHIBITORS;

EID: 33646270885     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2006.42.3.953589     Document Type: Review

References (28)

1. Mitchell, P.B., Mahli, G.S. Bipolar depression: Phenomenological overview and clinical characteristics. Bipolar Disord 2004, 6: 50-539.
2. American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 2002, 159 (4 Suppl.): 1-50.
3. Goodwin, G.M. Consensus of the British Association for Psychopharmacology. Evidence-based guidelines for treating bipolar disorder: Recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2003, 17: 149-73.
4. Yatham, L.M., Kennedy, S.H., O'Donovan, C. et al. Canadian Network for Mood and Anxiety treatments (CANMAT) guidelines for the management of patients with bipolar disorder: Consensus and controversies. Bipolar Disord 2005, 7 (Suppl. 3): 5-69.
5. Suppes, T., Dennehy, E.B. TIMA procedural manual; bipolar disorder algorithms. Available from: http://www.dshs.state.tx.us/mhprograms/TIMABD man.pdf
6. Keck, P.E. Jr., Perlis, R.H., Otto, M.W. et al. The expert consensus guideline series: Treatment of bipolar disorder 2004. Available from: http://www.psychguides.com
7. Zhang, W., Perry, K.W., Wong, D.T. et al. Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex. Neuropsychopharmacology 2000, 23: 250-62.
8. Gronier, B.S., Rasmussen, K. Electrophysiological effects of acute and chronic olanzapine and fluoxetine in the rat prefrontal cortex. Neurosci Letters 2003, 348: 196-200.
9. Koch, S., Perry, K.W., Bymaster, F.P. Brain region and dose effects of an olanzapine/fluoxetine combination on extracellular monoamine concentrations in the rat. Neuropharmacology 2004, 46: 232-42.
10. Seager, M., Huff, K.D., Barth, V.N., Phebus, L.A., Rasmussen, K. Fluoxetine administration potentiates the effect of olanzapine on locus coeruleus neuronal activity. Biol Psychiatry 2004, 55: 1103-9.
11. Seager, M.A., Barth, V.N., Phebus, L.A., Rasmussen, K. Chronic administration of olanzapine and fluoxetine activates locus coeruleus neurons in rats: Implications for bipolar disorder. Psychopharmacology 2005, 181: 126-33.
12. Yatham, L.N., Goldstein, J.M., Vieta, E. et al. Atypical antipsychotics in bipolar depression: Potential mechanisms of action. J Clin Psychiatry 2005, 66 (Suppl. 5): 40-8.
13. Tohen, M., Vieta, E., Calabrese, J. et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 2003, 60: 1079-88.
14. Symbyax U.S. and U.K. prescribing information as accessed through http://www.symbyax.com and some fluoxetine data from http://emc.medi cines.org.uk
15. Houston, J.P., Degenhardt, E.L., Ahl, J. et al. Suicidal ideation changes in depressed bipolar 1 patients with olanzapine-fluoxetine combination. 157th Annual Meeting of American Psychiatric Association: New Research abstracts: 266-267. New York 2004, Abst. NR707; Poster 72.
16. Shi, L., Manjoshi, M.A., Swindle, R. et al. Effects of olanzapine alone and olanzapine-fluoxetine combination on health-related quality of life in patients with bipolar depression: Secondary analyses of a double-blind placebo-controlled randomised clinical trial. Clin Ther 2004, 26: 125-34.
17. Corya S.A., Williamson, D., Case, M., Lin, D., Tohen, M. Open-label treatment with OFC and olanzapine in bipolar depression. 8th World Congress of Biological Psychiatry, Vienna 2005, Abst. NR 366.
18. Corya, S., Keck, P.E., Vieta, E., Dawes, J., Xu, W., Tohen, M. OFC treatment for bipolar depression in rapid cycling patients. 8th World Congress of Biological Psychiatry, Vienna 2005, Poster Abst. NR 365.
19. Brown, E., Williamson, D., Deldar, A., Keck, P.E., Adams, D.H. Olanzapine-fluoxetine combination versus lamotrigine for bipolar depression. 45th Annual Meeting New Clinical Drug Evaluation Unit, Boca Raton 2005, Program 266, Abst. 50.
20. Matthews, J.D., Bottonari, K.A., Polania, L.M. et al. An open study of olanzapine and fluoxetine for psychotic major depressive disorder: An interim analysis. J Clin Psychiatry 2002, 63: 1164-70.
21. Rothschild, A.J., Williamson, D.J., Tohen, M. et al. A double-blind, randomised study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. J Clin Psychopharmacol, 2004, 24: 365-73.
22. Corya, S., Dube, S.W., Andersen, T.M. et al. Olanzapine-fluoxetine combination for psychotic major depression. Int J Neuropsychopharmacol 2002, 5 (Suppl. 1): S144, Abst. P.3.E.026.
23. Corya, S., Andersen, S.W., Detke, H.C. et al. Long-term antidepressant efficacy and safety of olanzapine/fluoxetine combination: A 76-week open-label study. J Clin Psychiatry 2003, 64: 1349-56.
24. Shelton, R.C., Tollefson, G.D., Tohen, M. et al. A novel augmentation strategy for treating resistant major depression. Am J Psychiatry 2001, 158: 131-34.
25. Shelton, R.C., Williamson, D.J., Corya, S. et al. Olanzapine/fluoxetine combination for treatment-resistant depression: A controlled study of SSRI and nortriptyline resistance. J Clin Psychiatry 2005, 66: 1289-97.
26. Dube, S., Corya, S.A., Andersen, S.W., Detke, H.C., Blansette, S., Tollefson, G.D. Efficacy of olanzapine/fluoxetine combination in treatment-resistant depression. Annual Meeting of the American College of Neuropsychopharmacology, San Juan 2002, Program 94, Abst. 76.
27. Corya, S., Andersen, S.W., Paul, S. et al. Safety meta-analysis of olanzapine-fluoxetine combination versus olanzapine. Int J Neuropsychopharmacol 2002, 5 (Suppl. 1): S144, Abst. P.3.E.027.
28. Calabrese, J., Keck, P.E., MacFadden, W. et al. A randomised, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 2005, 162: 1351-60.